Clinical Trials · NCT03770728

Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea

Name: Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 3Efpeglenatide

Phase: Phase 3
Recruitment status: Terminated
Sponsor: Sanofi
Enrollment: 312
Start date: Aug 2019
Locations: 48 sites, 3 countries
Primary endpoint: Change From Baseline to Week 30 in HbA1c

View Efpeglenatide compound reference